Drug intelligence / Profile preview

Saginil Gel

Development stage
Unknown
Lead developer
Epitech
Modality
Small Molecules
Administration
Topical, Vaginal
01

Overview

Saginil Gel is a topically applied CE-marked medical device developed by Epitech Group for the symptomatic treatment of gynecological and vaginal inflammatory conditions. Its primary active ingredient is **adelmidrol**, a synthetic analogue of palmitoylethanolamide belonging to the ALIAmide (Autacoid Local Injury Antagonist Amide) class. The gel works by modulating the activity of local non-neuronal immune cells, particularly mast cells, to reduce inflammation, itching, burning, and pain. In addition to adelmidrol, the formulation contains sodium hyaluronate for hydration, phytosphingosine for barrier support, and quercetin for its antioxidant properties. It is specifically indicated for conditions such as vulvodynia, vulvar vestibulitis, and various forms of vaginitis, featuring bioadhesive properties to ensure prolonged local action.

Brand names
Saginil GelSAGINIL® GEL
02

Targets

TRPV1 (Transient receptor potential cation channel subfamily V member 1)CB (Cannabinoid receptors)GPR55 (G protein-coupled receptor 55)PPARA (Peroxisome proliferator-activated receptor alpha)

Beyond the preview

Go deeper on Saginil Gel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Saginil Gel.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call